CanBas Co., Ltd. (TYO:4575)

Japan flag Japan · Delayed Price · Currency is JPY
564.00
-17.00 (-2.93%)
Jun 3, 2026, 3:30 PM JST
Market Cap11.10B -42.9%
Revenue (ttm)n/a
Net Income-1.20B
EPS-61.10
Shares Out 19.11M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume236,200
Open574.00
Previous Close581.00
Day's Range548.00 - 574.00
52-Week Range549.00 - 1,558.00
Beta-0.84
Analystsn/a
Price Targetn/a
Earnings DateMay 14, 2026

About CanBas

CanBas Co., Ltd., a clinical stage biopharmaceutical company, engages in the basic research and clinical development of anti-cancer drugs. It develops CBP501, a compound which regulates the regulatory function of the protein calmodulin in Phase 2 clinical trials targeting non-small cell lung cancer; and CBS9106 for patients with advanced solid tumors. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 14
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4575
Full Company Profile

Financial Performance

Financial Statements